In vitro mucolytic activity of recombinant human deoxyribonuclease on equine tracheobronchial mucus.

This research investigates the effects of a type of enzyme derived from humans (recombinant human deoxyribonuclease) on the mucus found in the trachea and bronchi of horses suffering from lower airway diseases. The study finds that the enzyme was effective in reducing the thickness (viscosity) of mucus in certain horses, specifically those with a higher percentage of neutrophils in their mucus.

Details about the Study

• The study focused on the condition of the mucus found in the lower airways of horses, particularly those with lower airway diseases. Important properties of mucus such as its thickness, DNA concentration, and the size of the DNA were closely observed.
• Its primary aim was to determine the effectiveness of recombinant human deoxyribonuclease (rhDNase), a type of enzyme fabricated from human cells, on tracheobronchial mucus—mucus found in the trachea and bronchi of horses.

Participants

• The test subjects of the study were 11 horses all of which had lower airway diseases.
• These horses were then separated into two groups according to the cytology—cell makeup—of their mucus samples, specifically the percentage of neutrophils, a type of white blood cell.
• Group A consisted of five horses, their mucus samples having more than 60 per cent of neutrophils. Meanwhile, group B was made up of six horses, whose mucus contained fewer than 50 per cent neutrophils.

Results

• Prior to exposing the mucus to the rhDNase, the mucus from the horses in group A were observed to generally have a higher viscosity and DNA concentration compared to those from group B.
• A correlation was found between the DNA concentration and viscosity of the mucus samples from group A, suggesting that a higher DNA concentration leads to thicker mucus.
• The main finding of the study was that exposing the mucus to rhDNase effectively lowered its viscosity but only in the samples from group A. This means that the rhDNase was effective in reducing the thickness of mucus in the horses from group A, potentially providing these horses with relief from their lower airway diseases.

Conclusion

• This study is crucial as it presents a potential method to alleviate the discomfort and health issues that horses experience due to lower airway diseases.
• The results of the research suggest that administering rhDNase can potentially reduce the viscosity of mucus in horses, particularly those with a higher neutrophil count.
• This finding could have significant implications for veterinary medicine, especially in the treatment of lower airway diseases in horses.
• However, it is noteworthy that the rhDNase was found to be effective only in horses in group A. Further research might be required to explore its effectiveness in horses with different cytological profiles.